Standout Papers

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma 2007 2026 2013 2019 2.8k
  1. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma (2007)
    Gary R. Hudes, Michael A. Carducci et al. New England Journal of Medicine
  2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (2015)
    Christopher J. Sweeney, Yu‐Hui Chen et al. New England Journal of Medicine
  3. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (2008)
    Howard I. Scher, Susan Halabi et al. Journal of Clinical Oncology
  4. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study (2011)
    Karim Fizazi, Michael A. Carducci et al. The Lancet
  5. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016)
    Roland R. Griffiths, Matthew W. Johnson et al. Journal of Psychopharmacology
  6. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial (2018)
    Christos E. Kyriakopoulos, Yu‐Hui Chen et al. Journal of Clinical Oncology
  7. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (2015)
    Emmanuel S. Antonarakis, Changxue Lu et al. JAMA Oncology
  8. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide (2017)
    Emmanuel S. Antonarakis, Changxue Lu et al. Journal of Clinical Oncology

Immediate Impact

15 by Nobel laureates 6 from Science/Nature 118 standout
Sub-graph 1 of 15

Citing Papers

Prostate Cancer
2025 Standout
Renal Cell Carcinoma
2024 Standout
94 intermediate papers

Works of Michael A. Carducci being referenced

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
2024
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation
2019
and 54 more

Author Peers

Author Last Decade Papers Cites
Michael A. Carducci 17004 11207 10583 582 31.4k
Celestia S. Higano 16423 10138 6972 385 26.6k
Neal D. Shore 16380 9214 4687 752 24.3k
Mario A. Eisenberger 20808 8308 5019 375 26.6k
Eric J. Small 23669 13948 8706 603 34.8k
Martin Gleave 15695 8915 15487 679 32.0k
Fred Saad 23140 14980 7414 1.2k 35.4k
Oliver Sartor 14817 7792 5001 653 21.9k
George Wilding 11923 6748 9776 308 21.9k
Nicholas J. Vogelzang 22117 16878 8203 693 40.8k
Christopher J. Logothetis 9469 7820 6778 448 20.4k

All Works

Loading papers...

Rankless by CCL
2026